A ‘Fair’ Price For Rare Disease Cures: Payers, Physicians, Patients Weigh In
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
